about
Pattern of response of intact drosophila to known teratogensCongenital abnormalities and anticonvulsant drugsTreatment of pregnant women with a diagnosis of inflammatory bowel diseaseAnti-inflammatory and immunosuppressive drugs and reproductionProtein instability and functional defects caused by mutations of dihydro-orotate dehydrogenase in Miller syndrome patientsThe hazard evaluation system and information service: a physician's resource in toxicology and occupational medicine.Developmental delay in fetal aminopterin/methotrexate syndromeHuman pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing dataContraception for adolescents with lupus.Brief report: Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancyFurther case of aminopterin syndrome sine aminopterin in a Spanish child.Abortion induced with methotrexate and misoprostol.Species sensitivities and prediction of teratogenic potential.Use of methotrexate in juvenile idiopathic arthritis.Prevention of congenital abnormalities by periconceptional multivitamin supplementationEnvironmental teratogens.Mechanisms of action of teratogenic drugs.Fetal Renal Insufficiency Following Trastuzumab Treatment for Breast Cancer in Pregnancy: Case Report und Review of the Current Literature.Considering the Embryopathogenesis of VACTERL AssociationTreatment of inflammatory bowel disease and pregnancy: a review of the literature.Cancer chemotherapeutic agents as human teratogens.IBD medications during pregnancy and lactation.Potential human developmental toxicants and the role of animal testing in their identification and characterization.Chemical-biological reactions common to teratogenesis and mutagenesis.Dermatologic uses of methotrexate in children: indications and guidelines.Proceedings: Hazards of maternally administered drugs.Anticonvulsants during pregnancy: a danger to the developing fetus?Drug reactions and interactions.Effect of methotrexate administration on status of some essential trace elements and antioxidant enzymes in pregnant rats in late gestation.Fetal methotrexate and misoprostol exposure: the past revisited.An in ovo chicken model to study the systemic and localized teratogenic effects of valproic acid.Risks to the children born to mothers with autoimmune diseases.Further validation of FETAX: evaluation of the developmental toxicity of five known mammalian teratogens and non-teratogens.Potential teratogenic effects of allopurinol: a case report.Letter: international IBD practice guidelines -- authors' reply.Low-dose methotrexate in rheumatoid arthritis: effect and tolerance. An open trial and a double-blind randomized study.Maternal exposure to methotrexate and birth defects: a population-based study.Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study
P2860
Q23919791-8F9079EE-A7F8-4564-B9D3-C437FDA1CB5CQ24683057-AFE328D7-90D8-4B1C-8DD1-62C11D02C0D7Q28067821-3403DDE7-5C07-4A64-AC15-655D96F09E5CQ28218219-7C011D24-ACA7-4088-BE9F-640730A6FB73Q28274852-0714B1EF-772F-48FA-BFDB-8CABA74B4CD4Q28367423-A7FD0D57-9391-40D9-A7D1-B3D2FED4BC6FQ28369452-80F66CAD-5B91-48F7-8295-18393C8A8928Q31044246-559CBF2A-278C-4E8F-8B0E-386ABF489D49Q33813399-97DC4F85-900D-4C27-AF6B-B80B824C10A0Q33829396-1B20C359-5FD0-4D9F-9828-84E331EBA1BBQ34144186-16DD492C-E503-4F9E-8790-22C93CB0CB7BQ34713397-EC07F692-128B-4582-BF9D-7706C87347BAQ35035971-56AE3BDD-6A05-4318-A8D9-093050CBA4ACQ35070936-5B6153B5-7BF0-4E9F-8413-879E0E2301E9Q35188572-67D50A32-2F2E-41BA-A11D-E8B1FC56C3C5Q35662122-BCDD10F9-F5D1-4D7A-88A4-296A5CA3AEB2Q35667218-4B975668-2124-4024-84D8-8EF798E81055Q35789387-F28DE942-4FBF-4639-826E-BD4C89FC5ED5Q36802389-B4A99A9E-9B5D-442A-ABEE-48FB4ED15AE5Q37780963-51B7CB79-4F46-4B78-BD99-88556B6A8932Q38031187-5B1CC24E-8B0E-4296-A129-6C2818DB9A86Q38125114-B453E6EE-78C0-4A16-8F16-C82C6F020EF7Q38625359-74F5F630-CDA6-4FF9-9114-0840BAE6BB3DQ39139337-6BED22CA-0499-416C-97A1-692054355B3CQ39818932-BBFCD753-F5DE-487D-968D-EE138C43B2D1Q39874417-E9FC20E1-B78B-45FC-81EC-AD2559339A1DQ39939625-F4249F8B-DCA4-4211-BEBF-6504C4B7C578Q39994054-807CB4CC-4E1F-4AAB-A33B-C573092A8D05Q43244375-4167E044-4C7F-44A7-87DE-1421EFAD37D6Q44124443-DB812CE5-4DEA-41CD-8E2A-577B2D6D6457Q44157475-22C0E30D-8AEA-44EB-B70C-7D1B2C844387Q44202628-9A31DF43-E1B9-494C-B1E1-205885705CDBQ45738263-5C61A047-E753-42FB-846E-F4C5D3453B40Q52614655-91A06205-C759-4834-A220-A3B4BB7FE3F4Q53107725-376121B4-1E73-4EF5-918F-7455D190EA20Q54149961-391E0B32-8F03-4B4A-8E60-CD8B94947B57Q55128851-0A34B6E6-BEEF-4C41-8A08-2FDAD6EB1605Q56964882-F38E01EA-9045-426E-915E-9EA64F5A703B
P2860
description
1968 nî lūn-bûn
@nan
1968年の論文
@ja
1968年学术文章
@wuu
1968年学术文章
@zh
1968年学术文章
@zh-cn
1968年学术文章
@zh-hans
1968年学术文章
@zh-my
1968年学术文章
@zh-sg
1968年學術文章
@yue
1968年學術文章
@zh-hant
name
Methotrexate-induced congenital malformations.
@en
Methotrexate-induced congenital malformations.
@nl
type
label
Methotrexate-induced congenital malformations.
@en
Methotrexate-induced congenital malformations.
@nl
prefLabel
Methotrexate-induced congenital malformations.
@en
Methotrexate-induced congenital malformations.
@nl
P2093
P1476
Methotrexate-induced congenital malformations.
@en
P2093
Gaynor MF Jr
Milunsky A
P304
P356
10.1016/S0022-3476(68)80430-5
P407
P577
1968-06-01T00:00:00Z